A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This important study is testing a new medication, KarXT, for adults living with schizophrenia whose symptoms aren't fully controlled by their current treatments. Participants will be given either KarXT or a dummy pill (placebo) to see how safe and effective KarXT is. Researchers will carefully track changes in symptoms, how well people are doing in their daily lives, and overall health over a 6-week period. The main goal is to find out if KarXT can significantly improve symptoms compared to the placebo. This type of study, called a Phase 3 trial, is a crucial step towards potentially making new treatments available to people who need them.
At a glance
What is this study about?
Imagine you're living with schizophrenia, and even with the treatments you're receiving, your symptoms are still causing difficulties. This study is exploring a new medicine called KarXT that might offer another option for people in this situation. Researchers want to find out if KarXT can help reduce symptoms more effectively than a dummy medicine (called a placebo) given over six weeks.
This is a 'Phase 3' study, which means it's one of the final steps in testing a new medication before it might become widely available. Doctors and scientists need to be sure that new treatments are both safe and helpful. To do this, they compare the new medicine with a placebo – neither the participants nor their doctors will know who is getting which, to keep the results as fair and unbiased as possible.
The main thing the doctors will be looking at is how much a person's overall symptoms improve after six weeks. They will also look at other important things, like how well people are managing their daily lives, their general health, and specific types of symptoms like feeling overly excited or withdrawn. The aim is to gather strong evidence to see if KarXT could be a valuable new treatment option for people with schizophrenia.
Key takeaways
- This study is testing a new medicine called KarXT for adults with schizophrenia.
- It's for people whose symptoms aren't fully controlled by current treatments.
- Participants will receive either KarXT or a dummy pill (placebo) for 6 weeks.
- The main aim is to see if KarXT improves symptoms and overall well-being.
- 'Phase 3' means it's a key step towards potentially new treatments.
- Your participation helps advance understanding and potential new options for schizophrenia.
Who may be eligible?
To join this study, you need to be an adult, aged 18 or older. The study is open to anyone, regardless of their gender.
Crucially, you would need to have a diagnosis of schizophrenia and your current treatment shouldn't be fully controlling your symptoms. This means you're still experiencing significant difficulties, and your doctor thinks additional help might be beneficial.
There will be other detailed health requirements, and your doctor will check if your current medications or other health conditions mean this study isn't right for you. They will explain everything clearly during your screening visit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of schizophrenia?
- Are your current treatments not fully controlling your schizophrenia symptoms?
- Are you able to attend regular study appointments?
- Are you willing to consider taking a new, experimental medication or a placebo?
What does participation involve?
If you decide to take part, you'll first have a screening visit where doctors will check if the study is a good fit for you. Once enrolled, you'll be given either the new medicine, KarXT, or a dummy pill (placebo) – you won't know which one you're receiving. Both you and your study doctor will remain 'blinded' to this.
You'll take the study medication regularly as instructed, and you'll have several visits to the clinic over a 6-week period. During these visits, doctors and nurses will carefully check your health, ask about your symptoms, and see how you're feeling. They will use special scales and questions to measure any changes. After the 6 weeks of treatment, there will likely be follow-up appointments to monitor your health and well-being even after you stop taking the study drug. The total duration of your involvement will be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is a 'Phase 3' study?
It's one of the last stages of testing a new medicine, making sure it's safe and works well before it can be made available to everyone.
What is a 'placebo'?
A placebo is a dummy pill that looks like the real medicine but contains no active drug. It helps researchers compare the new medicine's effects properly.
Will I know if I'm getting the new medicine or the placebo?
No, neither you nor your study doctor will know. This helps ensure the study results are fair and accurate.
How long will I be involved in the study?
You'll be taking the study medication for 6 weeks, with follow-up appointments after that. The total time will be explained by the study team.
Can I stop participating at any time?
Yes, you have the right to withdraw from the study at any point, and your decision will not affect your normal medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.